# Novel Agents for Treatment of High-risk COVID-19 Positive Patients

> **NCT04374019** · PHASE2 · TERMINATED · sponsor: **Susanne Arnold** · enrollment: 13 (actual)

## Conditions studied

- COVID
- Sars-CoV2

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Camostat Mesilate
- **DIETARY_SUPPLEMENT:** Artemesia annua
- **DRUG:** Artesunate

## Key facts

- **NCT ID:** NCT04374019
- **Lead sponsor:** Susanne Arnold
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-01
- **Primary completion:** 2020-12-21
- **Final completion:** 2022-01-12
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** slow accrual,
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374019, "Novel Agents for Treatment of High-risk COVID-19 Positive Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04374019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*